Business Today
Loading...

Gilead nears deal to buy Immunomedics for more than $20 billion

A deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer called Metastatic Triple-Negative Breast Cancer, could be announced Monday if not sooner

twitter-logoReuters | September 13, 2020 | Updated 09:06 IST
Gilead nears deal to buy Immunomedics for more than $20 billion
An acquisition of Immunomedics would add to several deals Gilead inked this year with the aim of expanding its oncology portfolio

Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.

A deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer called Metastatic Triple-Negative Breast Cancer, could be announced Monday if not sooner, the Journal said, citing people familiar with the matter.

Discussions between Gilead and Immunomedics were initially centered around a partnership before shifting to a full-fledged takeover negotiation, the Journal added. Gilead and Immunomedics did not respond immediately to emailed requests from Reuters for comment.

Also read: Gilead says Indian licensees free to decide Remdesivir price

Shares of Immunomedics, which last month reported positive data from a late-stage confirmatory study for Trodelvy, have nearly doubled this year, giving the company a valuation of close to $10 billion.

An acquisition of Immunomedics would add to several deals Gilead inked this year with the aim of expanding its oncology portfolio.

It bought a 49.9% stake in cancer drug developer Pionyr Immunotherapeutics in June for $275 million, just months after paying $4.9 billion for Forty Seven Inc, maker of an experimental treatment that targets blood cancer.

Also read: Gilead raises 2020 sales forecast to include revenue from COVID-19 drug remdesivir

  • Print
  • COMMENT
BT-Story-Page-B.gif
A    A   A
close